Literature DB >> 25691647

Peptidyl aldehyde NK-1.8k suppresses enterovirus 71 and enterovirus 68 infection by targeting protease 3C.

Yaxin Wang1, Ben Yang2, Yangyang Zhai3, Zheng Yin4, Yuna Sun5, Zihe Rao6.   

Abstract

Enterovirus (EV) is one of the major causative agents of hand, foot, and mouth disease in the Pacific-Asia region. In particular, EV71 causes severe central nervous system infections, and the fatality rates from EV71 infection are high. Moreover, an outbreak of respiratory illnesses caused by an emerging EV, EV68, recently occurred among over 1,000 young children in the United States and was also associated with neurological infections. Although enterovirus has emerged as a considerable global public health threat, no antiviral drug for clinical use is available. In the present work, we screened our compound library for agents targeting viral protease and identified a peptidyl aldehyde, NK-1.8k, that inhibits the proliferation of different EV71 strains and one EV68 strain and that had a 50% effective concentration of 90 nM. Low cytotoxicity (50% cytotoxic concentration, >200 μM) indicated a high selective index of over 2,000. We further characterized a single amino acid substitution inside protease 3C (3C(pro)), N69S, which conferred EV71 resistance to NK-1.8k, possibly by increasing the flexibility of the substrate binding pocket of 3C(pro). The combination of NK-1.8k and an EV71 RNA-dependent RNA polymerase inhibitor or entry inhibitor exhibited a strong synergistic anti-EV71 effect. Our findings suggest that NK-1.8k could potentially be developed for anti-EV therapy.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25691647      PMCID: PMC4394787          DOI: 10.1128/AAC.00049-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

Review 1.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

Review 2.  Analysis of combinations of antiviral drugs and design of effective multidrug therapies.

Authors:  M N Prichard; C Shipman
Journal:  Antivir Ther       Date:  1996-01

3.  Satellite and defective RNAs of Cryphonectria hypovirus 3-grand haven 2, a virus species in the family Hypoviridae with a single open reading frame.

Authors:  B I Hillman; R Foglia; W Yuan
Journal:  Virology       Date:  2000-10-10       Impact factor: 3.616

4.  Acute flaccid paralysis in infants and young children with enterovirus 71 infection: MR imaging findings and clinical correlates.

Authors:  C Y Chen; Y C Chang; C C Huang; C C Lui; K W Lee; S C Huang
Journal:  AJNR Am J Neuroradiol       Date:  2001-01       Impact factor: 3.825

Review 5.  An overview of the evolution of enterovirus 71 and its clinical and public health significance.

Authors:  Peter C McMinn
Journal:  FEMS Microbiol Rev       Date:  2002-03       Impact factor: 16.408

6.  Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics.

Authors:  Peter S Dragovich; Thomas J Prins; Ru Zhou; Theodore O Johnson; Edward L Brown; Fausto C Maldonado; Shella A Fuhrman; Leora S Zalman; Amy K Patick; David A Matthews; Xinjun Hou; James W Meador; Rose Ann Ferre; Stephen T Worland
Journal:  Bioorg Med Chem Lett       Date:  2002-03-11       Impact factor: 2.823

7.  Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA.

Authors:  J Pelletier; N Sonenberg
Journal:  Nature       Date:  1988-07-28       Impact factor: 49.962

8.  Scavenger receptor B2 is a cellular receptor for enterovirus 71.

Authors:  Seiya Yamayoshi; Yasuko Yamashita; Jifen Li; Nobutaka Hanagata; Takashi Minowa; Taro Takemura; Satoshi Koike
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

9.  Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents.

Authors:  Chih-Jung Kuo; Jiun-Jie Shie; Jim-Min Fang; Guei-Rung Yen; John T-A Hsu; Hun-Ge Liu; Sung-Nain Tseng; Shih-Cheng Chang; Ching-Yin Lee; Shin-Ru Shih; Po-Huang Liang
Journal:  Bioorg Med Chem       Date:  2008-06-13       Impact factor: 3.641

Review 10.  Current progress in antiviral strategies.

Authors:  Zhiyong Lou; Yuna Sun; Zihe Rao
Journal:  Trends Pharmacol Sci       Date:  2014-01-14       Impact factor: 14.819

View more
  12 in total

1.  Activity-Based Protein Profiling Identifies ATG4B as a Key Host Factor for Enterovirus 71 Proliferation.

Authors:  Yang Sun; Qizhen Zheng; Yaxin Wang; Zhengyuan Pang; Jingwei Liu; Zheng Yin; Zhiyong Lou
Journal:  J Virol       Date:  2019-11-26       Impact factor: 5.103

2.  Discovery of Potent EV71 Capsid Inhibitors for Treatment of HFMD.

Authors:  Peng Li; Jun Yu; Fei Hao; Haiying He; Xuyang Shi; Jiao Hu; Li Wang; Chunyan Du; Xiao Zhang; Ya Sun; Fusen Lin; Zhengxian Gu; Deming Xu; Xinsheng Chen; Liang Shen; Guoping Hu; Jian Li; Shuhui Chen; Wei Xiao; Zhenzhong Wang; Qingming Guo; Xiujuan Chang; Xuyang Tian; Tianwei Lin
Journal:  ACS Med Chem Lett       Date:  2017-07-10       Impact factor: 4.345

3.  Structure of the Enterovirus 71 3C Protease in Complex with NK-1.8k and Indications for the Development of Antienterovirus Protease Inhibitor.

Authors:  Yaxin Wang; Lin Cao; Yangyang Zhai; Zheng Yin; Yuna Sun; Luqing Shang
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

4.  Enterovirus A71 antivirals: Past, present, and future.

Authors:  Jun Wang; Yanmei Hu; Madeleine Zheng
Journal:  Acta Pharm Sin B       Date:  2021-08-20       Impact factor: 14.903

5.  A Conserved Inhibitory Mechanism of a Lycorine Derivative against Enterovirus and Hepatitis C Virus.

Authors:  Yu Guo; Yaxin Wang; Lin Cao; Peng Wang; Jie Qing; Qizhen Zheng; Luqing Shang; Zheng Yin; Yuna Sun
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

6.  Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68.

Authors:  Liang Sun; Adam Meijer; Mathy Froeyen; Linlin Zhang; Hendrik Jan Thibaut; Jim Baggen; Shyla George; John Vernachio; Frank J M van Kuppeveld; Pieter Leyssen; Rolf Hilgenfeld; Johan Neyts; Leen Delang
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

7.  A Novel Enterovirus 71 (EV71) Virulence Determinant: The 69th Residue of 3C Protease Modulates Pathogenicity.

Authors:  Bingqing Li; Yingying Yue; Yajie Zhang; Zenglin Yuan; Peng Li; Nannan Song; Wei Lin; Yan Liu; Lichuan Gu; Hong Meng
Journal:  Front Cell Infect Microbiol       Date:  2017-02-03       Impact factor: 5.293

8.  Human Enterovirus 68 Interferes with the Host Cell Cycle to Facilitate Viral Production.

Authors:  Zeng-Yan Wang; Ting Zhong; Yue Wang; Feng-Mei Song; Xiao-Feng Yu; Li-Ping Xing; Wen-Yan Zhang; Jing-Hua Yu; Shu-Cheng Hua; Xiao-Fang Yu
Journal:  Front Cell Infect Microbiol       Date:  2017-02-08       Impact factor: 5.293

9.  Suramin interacts with the positively charged region surrounding the 5-fold axis of the EV-A71 capsid and inhibits multiple enterovirus A.

Authors:  Peijun Ren; Yimei Zheng; Wenqi Wang; Liping Hong; Françis Delpeyroux; Fernando Arenzana-Seisdedos; Ralf Altmeyer
Journal:  Sci Rep       Date:  2017-02-20       Impact factor: 4.379

Review 10.  Roles of the Picornaviral 3C Proteinase in the Viral Life Cycle and Host Cells.

Authors:  Di Sun; Shun Chen; Anchun Cheng; Mingshu Wang
Journal:  Viruses       Date:  2016-03-17       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.